There are currently 117 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders
NCT05899348
Recruiting
People with psychotic disorders experience a high level of functional disability, and a major contributor to this disability is introspective accuracy, which is defined as inaccurate judgements of one's abilities and performance on tasks. Yet, no intervention has directly targeted introspective accuracy for psychotic illnesses. This trial will evaluate a new intervention, called iTEST, that uses mobile devices to train people with psychotic disorders to improve introspective accuracy and, ultima... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/08/2024
Locations: University of California, San Diego, La Jolla, California +1 locations
Conditions: Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
Register for Updates
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia
NCT05643196
Recruiting
This is a single-site, phase 2, sham-controlled random-order cross-over pilot trial of PLIFUS targeting the right GPi in individuals with schizophrenia. Twelve individuals with schizophrenia who report continuous hallucinations or delusions of mild or greater severity will receive one session of PLIFUS and one session of sham PLIFUS in random order, one week apart. If no effect of PLIFUS is detected on measures of functional connectivity or psychotic symptoms in the first four completers, the tr... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/05/2024
Locations: NYU Langone Brooklyn, Brooklyn, New York +1 locations
Conditions: Schizophrenia, Schizophrenia Schizoaffective
Register for Updates
Genetic Study of Schizophrenia
NCT00001486
Recruiting
This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizoaffective Disorder, Schizophrenia
Register for Updates
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
NCT04860830
Recruiting
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or planning a trip so that they arrive on time. The purpose of this study is to find out whether a medicine called iclepertin improves learning and memory in people with schizophrenia. Participants are put... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/02/2024
Locations: Advanced Research Center, Inc., Anaheim, California +125 locations
Conditions: Schizophrenia
Register for Updates
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190
Recruiting
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2024
Locations: University of California, Los Angeles, Los Angeles, California +6 locations
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
CLOZAPINE Response in Biotype-1
NCT04580134
Recruiting
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/01/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Register for Updates
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
NCT05276050
Recruiting
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS and/or follow-ups.
Gender:
All
Ages:
Between 22 years and 65 years
Trial Updated:
03/28/2024
Locations: The University of Texas Health Science Center, Houston, Houston, Texas
Conditions: Smoking Cessation, Nicotine Addiction, Schizophrenia
Register for Updates
What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia
NCT05282186
Recruiting
This project proposes to conduct the first study of the predictive utility of olfactory hedonic measurement for targeted psychosocial rehabilitation in schizophrenia. The information gathered from the project is of considerable public health relevance, in that, through simple, reliable olfactory assessment, it will provide knowledge about which individuals are most likely to benefit from these psychosocial interventions. Such information is crucial for tailoring existing interventions and develo... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/27/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Schizophrenia
Register for Updates
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
NCT05030272
Recruiting
The study team will conduct a Multisite Randomized Controlled Trial to evaluate the advantages and disadvantages of two approaches for quitting smoking among people with serious mental illness (SMI). The study will compare a novel app tailored to people with SMI, Quit on the Go, to a standard of care smoking cessation intervention. We will test the effectiveness of the Quit on the Go app, an intervention that has demonstrated feasibility and acceptability in the target population, as a tool for... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: University at Buffalo, Buffalo, New York +2 locations
Conditions: Tobacco Use Disorder, Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Recurring Major Depressive Disorder, Persistent Depressive Disorder
Register for Updates
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
NCT04296604
Recruiting
In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/20/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Traumatic Brain Injury, Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder, Borderline Personality Disorder, Substance Use Disorders
Register for Updates
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591
Recruiting
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Miami, Florida +10 locations
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
A Study of ANAVEX3-71 in Adults With Schizophrenia
NCT06245213
Recruiting
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
03/19/2024
Locations: CenExel Hassman Research Institute, Marlton, New Jersey
Conditions: Schizophrenia
Register for Updates